Opinion|Videos|March 19, 2025
New Approvals in HER2-Positive BTC: Zanidatamab - Key Findings from HERIZON-BTC-01 Study
Panelists discuss how the HERIZON-BTC-302 study demonstrated zanidatamab's efficacy in HER2-positive biliary tract cancer (BTC) with key end points presented at ASCO GI, while sharing insights on optimal dosing strategies and early real-world experience with this newly approved agent in the second-line setting.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Zanidatamab was recently approved. What were some key end points from the HERIZON-BTC-302 study at ASCO GI and what are your impressions?
- What is your dosing strategy with zanidatamab? Dr Ellis, can you share some highlights from a poster looking at optimizing zanidatamab’s dosing?
- For those with experience using zanidatamab in the 2L, what has your experience been? What outcomes have you seen in patients so far?
Advertisement
Related to this article
Experts break down key melanoma data and trends from the 2026 ESMO Congress.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.
Durvalumab plus BCG is now an approved first-line option for high-risk NMIBC, but better BCG delivery and biomarker-guided selection should shape its use.
The FDA has approved amivantamab and hyaluronidase-lpuj for metastatic head and neck squamous cell carcinoma.
A UCLA-led study suggests routine mammograms or other breast imaging may not benefit women after double mastectomy for DCIS.
Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.
Are we ready to “take that fork in the road” and move palliative/supportive care into routine cancer care?
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
3
Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL
4
Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
5